Webinar

Multi-Modal Connected Workflow for Cardiac Safety Assessment of Drugs Using hiPSC-Derived Cardiomyocytes

February 1, 2022 

Session 1: 9AM EST | 2PM GMT | 3PM CET
Session 2: 11AM PST | 2PM EST | 7PM GMT


Pharmaceutical compounds need to undergo safety assessment screening. These in vitro frontline screening assays should be multi-parametric, scalable and mechanistic enabling a high degree of predictivity and specificity. Increasingly, cardiomyocytes are being utilized for the safety assessment of pharmaceutical compounds as they represent a highly relevant model system and can potentially provide broad information regarding electrical, mechanical, metabolic and structural liabilities.

In this webinar, we will discuss a connected workflow using human iPSC-derived cardiomyocytes (hiPSC-CMs) for microelectrode-based measurements (including viability and contraction, live-cell imaging, mitochondrial toxicity, and cell metabolism) as a frontline screening assay for safety assessment of pharmaceutical drug compounds.


Attend this webinar to:

  • Learn about technologies for studying viability, contractility, electrophysiology, and metabolism of cardiomyocytes
  • Gain a deeper understanding of in vitro cardiotoxicity screening strategy
  • How to extract relevant information on adverse effects of drug from the same cell preparation

Speaker Information:

Ryan-MCG-Round
Ryan McGarrigle
Research Scientist
Agilent Technologies
XiaoyuZ-Round
Xiaoyu Zhang
Senior Research Scientist
Agilent Technologies

Attend this webinar to:

 

  • Learn about technologies for studying viability, contractility, electrophysiology, and metabolism of cardiomyocytes
  • Gain a deeper understanding of in vitro cardiotoxicity screening strategy
  • How to extract relevant information on adverse effects of drug from the same cell preparation

Register for FREE Now!